Finance

As valuation swells above $380M, Syncona-backed Gyroscope draws $148M series C, mulls listing

Ophthalmic play could be third gene therapy IPO from Syncona’s portfolio

The ophthalmic play could become the third gene therapy company to go public from Syncona’s portfolio.

Gene